Gene Therapy for Fanconi Anemia Complementation Group A

  • STATUS
    Recruiting
  • participants needed
    5
  • sponsor
    Rocket Pharmaceuticals Inc.
Send
Updated on 19 February 2024
See if I qualify

Summary

The objective of this study is to assess the therapeutic efficacy of a hematopoietic cell-based gene therapy for patients with Fanconi anemia, subtype A (FA-A).

Hematopoietic stem cells from mobilized peripheral blood of patients with FA-A will be transduced ex vivo (outside the body) with a lentiviral vector carrying the FANCA gene. After transduction, the corrected stem cells will be infused intravenously back to the patient with the goal of preventing bone marrow failure.

Description

This is a pediatric open-label Phase II clinical trial to assess the efficacy of a hematopoietic gene therapy consisting of autologous CD34+ enriched cells transduced with a lentiviral vector carrying the FANCA gene in subjects with FA-A.

Enriched CD34+ hematopoietic stem cells will be transduced ex vivo with the therapeutic lentiviral vector and infused via intravenous infusion following transduction without any prior conditioning.

Details
Condition Fanconi Anemia Complementation Group A
Age 1years - 100years
Treatment RP-L102
Clinical Study IdentifierNCT04248439
SponsorRocket Pharmaceuticals Inc.
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Fanconi anemia as diagnosed by chromosomal fragility assay of cultured lymphocytes in the presence of DEB or a similar DNA-crosslinking agent
Patients of the complementation group FA-A
Minimum age: 1 year and a minimum weight of 8 kg
At least 30 CD34+ cells/L are determined in one bone marrow (BM) aspiration within 3 months prior to CD34+ cell collection OR (see subsequent criterion)
If the number of CD34+ cells/ L in BM is in the range of 10-29, peripheral blood (PB) parameters should meet two of the three following criteria
Hemoglobin: 11g/dL
Neutrophils: 900 cells/L
Platelets: 60,000 cells/L
Provide informed consent in accordance with current legislation
Women of childbearing age must have a negative urine pregnancy test at the baseline visit, and accept the use of an effective contraception method during participation in the trial

Exclusion Criteria

Subjects with an available and medically eligible HLA-identical sibling donor
Evidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities other than those reported as variant(s) of normal in BM aspirate analysis. This assessment should be made by valid studies conducted within the 3 months before the subject commences the stem cell mobilization/collection procedures of the clinical trial
Subjects with somatic mosaicism associated with stable or improved counts in all PB cell lineages. (If T-lymphocyte chromosomal fragility analysis indicates potential mosaicism, a medically significant decrease (1 NCI CTCAE grade) in at least one blood lineage over time must be documented to enable eligibility, as should <5% resistance of bone marrow colony forming cells (CFCs) to 10nM MMC; whenever possible potential mosaicism should also be evaluated by gene sequencing of MMC-resistant CFCs)
Lansky performance status 60%
Any concomitant disease or condition that, in the opinion of the Principal Investigator, renders the subject unfit to participate in the study
Pre-existing sensory or motor impairment grade 2 according to the criteria of the NCI
Pregnant or breastfeeding women
Hepatic dysfunction as defined by either
Bilirubin >3.0 the upper limit of normal (ULN) or
Alanine aminotransferase (ALT) > 5.0 ULN or
Aspartate aminotransferase (AST) > 5.0 ULN
For subjects with bilirubin, ALT or AST above ULN, a workup to identify the
etiology of liver abnormality should be conducted prior to confirmation of
eligibility as stipulated in exclusion criterion 5, including evaluation of
viral hepatitis, iron overload, drug injury or other causes
\. Renal dysfunction requiring either hemodialysis or peritoneal dialysis
\. Pulmonary dysfunction as defined by either
Need for supplemental oxygen during the prior 2 weeks in absence of acute infection or
Oxygen saturation by pulse oximetry <90%. 11\. Evidence of active metastatic or locoregionally advanced malignancy for which survival is anticipated to be less than 3 years. 12\. Subject is receiving androgens (i.e. danazol, oxymetholone). 13\. Subject is receiving other investigational therapy for treatment/prevention of FA-associated bone marrow failure
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.